

Results of 2024 Annual General Meeting

SYDNEY Australia, 6 November 2024: In accordance with ASX Listing Rule 3.13.2 and section 251AA of the *Corporations Act 2001* (Cth), the results of the Recce Pharmaceuticals Ltd (**ASX:RCE, FSE:R9Q**) Annual General Meeting held today at 1:30pm (AEDT) are attached.

All resolutions put to the Annual General Meeting were decided by way of poll.

This announcement has been approved for release by Recce Pharmaceuticals Board.

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing a New Class of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral pathogens.

Recce's anti-infective pipeline includes three patented, broad-spectrum, synthetic polymer anti-infectives: RECCE® 327 (R327) as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria, including their superbug forms; RECCE® 435 (R435) as an orally administered therapy for bacterial infections; and RECCE® 529 (R529) for viral infections. Through their multi-layered mechanisms of action, Recce's anti-infectives have the potential to overcome the processes utilised by bacteria and viruses to overcome resistance – a current challenge facing existing antibiotics.

The World Health Organization (WHO) added R327, R435, and R529 to its list of antibacterial products in clinical development for priority pathogens, recognising Recce's efforts to combat antimicrobial resistance. The FDA granted R327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act, providing Fast Track Designation and 10 years of market exclusivity post approval. R327 is also included on The Pew Charitable Trusts' Global New Antibiotics in Development Pipeline as the sole synthetic polymer and sepsis drug candidate in development.

Recce wholly owns its automated manufacturing, supporting current clinical trials. Recce's anti-infective pipeline aims to address synergistic, unmet medical needs by leveraging its unique technologies.



ASX: RCE, FSE: R9Q

Head Office: Level 23, 180 George St, Salesforce Tower, SYDNEY NSW 2000 T +61 (02) 9256 2505

R&D Centre - Perth: Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 T +61 (8) 9362 9860

Washington Office: 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA

Disclosure of Proxy Votes

Recce Pharmaceuticals Ltd

Annual General Meeting

Wednesday, 06 November 2024



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

| Resolution | Decided by Show of Hands (S) or Poll (P) | Total Number of Proxy Votes exercisable by proxies validly appointed | Proxy Votes | | | | Poll Results (if applicable) | | | Results | |
|--|--|--|----------------------|----------------------|------------|--------------------|------------------------------|----------------------|------------|------------|--------------------|
| | | | FOR | AGAINST | ABSTAIN | PROXY'S DISCRETION | FOR | AGAINST | ABSTAIN | OUTCOME | S250U APPLICABLE |
| 1 Adoption of Remuneration Report | P | 61,614,271 | 44,988,874 73.02% | 16,257,675 26.39% | 204,008 | 367,722 0.60% | 47,403,295 74.41% | 16,300,281 25.59% | 3,504,008 | - | Yes ^(a) |
| 2 Spill Resolution (Conditional Resolution) | P | 61,432,876 | 7,490,889 12.19% | 53,574,265 87.21% | 385,403 | 367,722 0.60% | 7,643,155 12.03% | 55,879,026 87.97% | 3,685,403 | Not Passed | n/a |
| 3 Re-election of Dr Alan Dunton as Director | P | 74,726,636 | 58,437,095 78.20% | 15,893,819 21.27% | 243,504 | 395,722 0.53% | 60,901,011 79.30% | 15,893,819 20.70% | 3,564,615 | Passed | n/a |
| 4 Re-election of Alistair McKeough as Director | P | 74,726,636 | 58,434,723 78.20% | 15,896,191 21.27% | 243,504 | 395,722 0.53% | 60,898,639 79.30% | 15,896,191 20.70% | 3,564,615 | Passed | n/a |
| 5 ASX Listing Rule 7.1A Approval of Future Issue of Securities | P | 74,959,676 | 73,879,226 98.56% | 704,728 0.94% | 10,464 | 375,722 0.50% | 74,877,350 93.21% | 5,451,631 6.79% | 30,464 | Passed | n/a |
| 6 Ratification of Prior Issue of Placement Shares | P | 54,485,407 | 53,764,777 98.68% | 293,658 0.54% | 13,953,918 | 426,972 0.78% | 54,814,151 91.58% | 5,040,561 8.42% | 13,973,918 | Passed | n/a |
| 7 Ratification of Prior Issue of Consultant Shares | P | 72,723,215 | 71,857,430 98.81% | 438,813 0.60% | 30,954 | 426,972 0.59% | 74,353,707 99.41% | 438,813 0.59% | 3,350,954 | Passed | n/a |
| 8 Appointment of Auditor | P | 74,910,140 | 74,457,168 99.40% | 14,000 0.02% | 60,000 | 438,972 0.59% | 80,285,445 99.98% | 14,000 0.02% | 60,000 | Passed | n/a |

For personal use only



| Resolution | Decided by Show of Hands (S) or Poll (P) | Total Number of Proxy Votes exercisable by proxies validly appointed | Proxy Votes | | | | Poll Results (if applicable) | | | Results | |
|---|--|--|----------------------|--------------------|-----------|--------------------|------------------------------|--------------------|-----------|---------|------------------|
| | | | FOR | AGAINST | ABSTAIN | PROXY'S DISCRETION | FOR | AGAINST | ABSTAIN | OUTCOME | S250U APPLICABLE |
| 9 Adoption of New Constitution | P | 74,832,256 | 74,261,608 99.24% | 133,676 0.18% | 137,884 | 436,972 0.58% | 80,065,663 99.83% | 133,676 0.17% | 160,106 | Passed | n/a |
| 10 Renewal of Proportional Takeover Provisions | P | 74,883,756 | 73,951,032 98.75% | 485,288 0.65% | 86,384 | 447,436 0.60% | 76,428,479 99.37% | 485,288 0.63% | 3,445,678 | Passed | n/a |
| 11 Selective Capital Reduction | P | 27,569,804 | 27,061,661 98.16% | 140,421 0.51% | 2,994,327 | 367,722 1.33% | 29,518,688 99.53% | 140,421 0.47% | 6,294,327 | Passed | n/a |
| 12 Approval of Issue of Options to Dr John Prendergast, Director of the Company | P | 26,970,427 | 25,867,521 95.91% | 727,184 2.70% | 2,848,026 | 375,722 1.39% | 26,876,222 96.91% | 857,955 3.09% | 7,473,581 | Passed | n/a |
| 13 Approval of Issue of Options to James Graham, Director of the Company | P | 26,970,427 | 25,836,521 95.80% | 758,184 2.81% | 2,848,026 | 375,722 1.39% | 26,845,222 96.79% | 888,955 3.21% | 7,473,581 | Passed | n/a |
| 14 Approval of Issue of Options to Michele Dilizia, Director of the Company | P | 26,970,427 | 25,784,299 95.60% | 810,406 3.00% | 2,848,026 | 375,722 1.39% | 26,814,111 96.61% | 941,177 3.39% | 7,452,470 | Passed | n/a |
| 15 Approval of Issue of Options to Dr Justin Ward, Director of the Company | P | 26,970,427 | 25,784,299 95.60% | 810,406 3.00% | 3,149,470 | 375,722 1.39% | 26,814,111 96.61% | 941,177 3.39% | 7,753,914 | Passed | n/a |
| 16 Approval of Issue of Options to Dr Alan Dunton, Director of the Company | P | 26,970,427 | 24,110,756 89.40% | 2,483,949 9.21% | 2,848,026 | 375,722 1.39% | 25,119,457 90.57% | 2,614,720 9.43% | 7,473,581 | Passed | n/a |
| 17 Approval of Issue of Options to Alistair McKeough, Director of the Company | P | 26,970,427 | 24,101,656 89.36% | 2,493,049 9.24% | 2,848,026 | 375,722 1.39% | 25,110,357 90.54% | 2,623,820 9.46% | 7,473,581 | Passed | n/a |

Note: (a) As more than 25% of the votes cast on Resolution 1 were against the adoption of the Remuneration Report, this constitutes a 'second strike' under section 250U of the Corporations Act 2001 (Cth), however Resolution 2, the spill resolution, was not passed.

